On September 22, the first shipment ceremony of the Class 1 innovative drug Saint Relais (Pemoxatide Injection) independently developed by Hansoh Pharmaceutical was officially held.

A refrigerated truck loaded with Saint Relais slowly drove out of the production base. Going nationwide marks that Saint Relais is about to be officially put into clinical use, bringing new hope for efficient and high-quality treatment to the vast number of patients with renal anemia.

'Once a month, you can reach the standard with peace of mind.' Hansoh Pharmaceutical Saint Relais is the world's only highly specific small peptide agonist of EPO receptors. It has potential safety advantages and only needs to be administered once every 4 weeks, greatly reducing the frequency of administration and helping to significantly improve patient treatment.

Saint Relais was approved for marketing in June this year and is suitable for the treatment of anemia caused by chronic kidney disease (CKD), including adult non-dialysis patients who are not receiving erythropoiesis stimulating agents (ESA), and those who are receiving short-acting erythropoiesis-stimulating agents. Adult dialysis patients treated with EPO. Saint Relais has filled the gap in the new generation of ESA monthly preparations in my country and even the world, and officially opened a new era in the treatment of renal anemia in CKD in my country.

Following the successful launch of Xinyue , Amele , Hengmu , Hansoh Xinfu , Fulaimai and Mailinda and entering the national medical insurance directory to benefit the majority of patients, Saint Relais has become the approved product of Hansoh Pharma. 's seventh blockbuster innovative drug.

Strive for excellence and achieve perfection. Hansoh Pharma will continue to focus on its advantageous areas, accelerate the construction of a global innovation ecosystem, give full play to the advantages of the entire industry chain, strive to develop more high-quality new drugs and good drugs, and make unremitting efforts to improve the quality of human life.

About CKD renal anemia

Renal anemia is one of the most common complications of CKD. Epidemiological data show that the prevalence of CKD among Chinese adults is 10.8%, and more than 50% of them are anemic [1] and with the progression of CKD, the prevalence of renal anemia continues to increase, and the overall anemia rate among non-dialysis CKD patients is The prevalence rate is 28.5%-72.0%, while the prevalence rate of anemia among dialysis patients is as high as 91.6%-98.2%[2]. The latest data shows that as of the end of 2022, the number of dialysis patients in my country (including Hong Kong, Macao and Taiwan) has reached 1.1 million, an increase of 3.6 times compared with 2011. It is the country with the most dialysis patients in the world, and the number of patients is still rising rapidly [3]. A large number of clinical needs need to be met urgently.

About Saint Relais

Saint Relais (Pemosatide Injection) is 'the world's only highly specific small peptide agonist for EPO receptors' independently developed by Hansoh Pharmaceuticals. It was approved for marketing by the National Medical Products Administration (NMPA) in June 2023. It is suitable for the treatment of anemia caused by chronic kidney disease (CKD), including adult non-dialysis patients who are not receiving erythropoiesis-stimulating agents (ESA), and adult dialysis patients who are receiving short-acting erythropoietin (EPO) therapy.

Contact:

Tel: 0518-83096666

Email: PV.SERVICE@hspharm.com

(C) 2023 Electronic News Publishing, source ENP Newswire